

Amendments to the Claims and Listing of the Claims:

Please cancel claims 1, 3, 8-11, 14 and 17-19, without prejudice, amend claims 4, 7, 12, 13, 15, 16, 32-34 and 36, without prejudice, and insert new claim 37, as set forth in the following listing of the claims, which replaces all prior listings of the claims:

1. - 3. (Cancelled)

4. (Currently Amended) The composition according to claim [[1]]37, comprising a salt of zolpidem selected from the hydrochloride, mesilate, citrate, nitrate, lactate, maleate, tartrate, phosphate, succinate, fumarate and gluconate salts.

5. (Previously Presented) The composition according to claim 4, wherein the salt is the tartrate salt.

6. - 11. (Cancelled)

7. (Currently Amended) The composition according to claim [[1]]37, comprising from 24 to 80 mg/ml of zolpidem (expressed as the free base).

8. - 11. Cancelled)

12. (Currently Amended) The composition according to claim [[11]]37, comprising 50 to 700 mg/ml SBE-CD.

13. (Currently Amended) The composition according to claim [[1]]37, having a pH of from 3.0 to 8.0.

14. (Cancelled)

15. (Currently Amended) The composition according to claim [[14]]37, comprising from 0.5 to 50 mg/ml of chitosan, a salt, a derivative thereof or a salt of a derivative thereof.

16. (Currently Amended) The composition according to claim [[1]]37, wherein the composition is an aqueous solution and comprises from 30 to 60 mg/ml of zolpidem tartrate, 100 to 300 mg/ml SBE-CD and 2 to 10 mg/ml of chitosan glutamate.

17. - 31. (Cancelled)

32. (Withdrawn-Currently Amended) A method of administering zolpidem or a pharmaceutically acceptable salt thereof to a patient in need thereof, which method ~~comprise~~ comprises the intranasal administration of a composition as defined in claim ~~[[1]]~~37.

33. (Withdrawn-Currently Amended) A method of treating or preventing insomnia, which method comprises the intranasal administration of a composition as defined in claim ~~[[1]]~~37.

34. (Withdrawn-Currently Amended) A method of treating a neurological disorder or Parkinson's disease, which method comprises the intranasal administration of a composition as defined in claim ~~[[1]]~~37.

35. (Withdrawn-Previously Presented) A method according to claim 34, wherein the neurological disorder is one arising from brain trauma, stroke or spinocerebellar ataxia.

36. (Withdrawn-Currently Amended) A nasal drug delivery device or a dose cartridge for use in a nasal drug delivery device comprising a composition as defined in claim ~~[[1]]~~37.

37. (New) A composition in the form of an aqueous solution for nasal delivery of zolpidem or a pharmaceutically acceptable salt thereof, wherein the composition comprises:

- (a) 16 to 97 mg/ml of zolpidem (expressed as the free base);
- (b) sulfobutylether β -cyclodextrin (SBE-CD); and
- (c) chitosan, a salt, or a derivative thereof formed by bonding acyl and/or alkyl groups with the hydroxyl groups, but not the amino groups of chitosan or a salt of the derivative thereof.